Remed Co.Ltd (302550) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Remed Co.Ltd KRW 371, price KRW 2,615, upside -85.8%, quality 49 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Structural break:
The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Weakest SetupStrongly overvalued and low quality.
!Fair value 371.24 KRW · Strongly overvalued (−86%)
!Quality 49/100
!Mixed Growth(revenue 5y +8.1 %/yr)
!Thin margins · 4.7% net margin (TTM)
✓Low debt · generates free cash flow
✓Ranks above peers(6/9)
!Narrow moat35/100
!Evidence only low, so the estimate is less certain
Watch Remed Co.Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus.
Show more
Remed Co.,Ltd. engages in the manufacture and supply of medical devices worldwide. The company offers transcranial magnetic stimulator, a technology for the treatment of disorders, such as stroke, autism, dementia, Parkinson's disease, developmental disorders, and tinnitus. It also offers neuro magnetic stimulation systems for helping blood circulation, treating pain, neurons, regenerating cells, and contraction and relaxation of muscles, as well as core muscle strengthening magnetic stimulation to enable building toned and shaped muscles. In addition, the company provides extracorporeal shock wave therapy; and technology to activate the sensory function of prostate and strengthen the pelvic floor muscle by stimulating them with electromagnetic pulse. The company was formerly known as CR Technology Co., Ltd. and changed its name to Remed Co., Ltd. in 2013. Remed Co., Ltd. was founded in 2003 and is headquartered in Daejeon, South Korea.
Stock analysis
Remed Co.Ltd (302550) currently trades at 2,615 KRW, while our model-based Fair Value estimate is 371.24 KRW, implying the stock looks roughly 604.2% overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 923.70 KRW per share, and 0 of the 24 models we run sit above the 2,615 KRW price.
Bear case: the Earnings-Based group reads lowest at 181.63 KRW, and 24 of the 24 models stay below the price. Evidence for this calculation is low.
Scenario range: 351.08 KRW (bear) to 448.96 KRW (bull), the price of 2,615 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 49/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Remed Co.Ltd reported revenue of 24.5B KRW in FY2025 versus 20.2B KRW in FY2021, a compound +5.0%/yr. Reported net income was 526M KRW in FY2025, compounding −8.5%/yr from FY2021.
Key figures
Market cap 80.8B KRW (≈ $59.4M) · P/S ratio 3.21 · Net margin 2.1% · Return on equity 1.8% · Return on assets (EBIT) 1.7% · Operating margin 9.5% · Revenue (TTM) 25.2B KRW · Revenue growth (YoY) +11.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (medium confidence).
What moves the price
The share trades about 29% below its 52-week high and 5% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −86%, 302550 screens richer than that median.
Fair Value models
Bear 351.08 KRWFair Value 371.24 KRWBull 448.96 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.65/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−4.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.6%
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−47.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−47.7%
Dividend (yield on the price)0.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.10% → 3%
⚠ Revenue per share shrinking 20.2%/yr over ~6Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+33.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +30.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks
Beats the industry median on 6/9 measures
Overall it ranks above its industry peers.
Valuation
Quality Score49 · Below median
Fair Value upside−86% · Bottom 25%
Profitability
Return on equity (TTM)2% · Above median
Return on assets1% · Above median
Net margin (TTM)5% · Above median
Operating margin (TTM)10% · Above median
Growth and dividend
Revenue growth11% · Above median
Balance sheet
Debt / equity0.07× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/FCF0.0× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)57· sector 31
PAST (return on equity)7· sector 7
HEALTH (low debt)97· sector 97
DIVIDEND (yield)0· sector 40
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Remed Co.Ltd Fair Value". https://www.fairvalue-calculator.com/stock/302550
Frequently asked questions
Is Remed Co.Ltd (302550) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 371.24 KRW versus a price of 2,615 KRW, about −86% upside (overvalued).
What is the fair value of 302550?
Our model-based fair value for Remed Co.Ltd is 371.24 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,615 KRW.
What is the quality score of 302550?
Remed Co.Ltd has a Quality Score of 49/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Remed Co.Ltd (302550)?
Our model-based price target is the fair value of 371.24 KRW (as of Sep 24, 2026) from 24 valuation models. Cautious scenario 351.08 KRW, optimistic scenario 448.96 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Remed Co.Ltd stock forecast for 2026?
Our models put fair value at 371.24 KRW, about −86% upside versus a price of 2,615 KRW (overvalued). Cautious scenario 351.08 KRW, optimistic scenario 448.96 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Remed Co.Ltd (302550)?
Remed Co.Ltd reported trailing-twelve-month revenue of about 25.2B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into Remed Co.Ltd (302550)?
For today's price to be fair in a discounted-cash-flow model, Remed Co.Ltd would have to grow free cash flow by +33.0 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.1 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 302550 use?
Our models discount Remed Co.Ltd at 11.9 %: a base by market capitalisation (micro), damped by beta 0.64, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Remed Co.Ltd that is +33.0 % per year a year over ten years, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Remed Co.Ltd (302550) delivered so far?
Over the past 5 years revenue at Remed Co.Ltd grew +8.1 % a year. The price currently implies +33.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Remed Co.Ltd (302550) growing?
The median revenue growth in the sector is +4.2 % a year. That is the yardstick for the growth priced into Remed Co.Ltd (+33.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Remed Co.Ltd (302550)?
The free-cash-flow yield on the price is 1.89 %: that much free cash flow Remed Co.Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Remed Co.Ltd (302550)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Remed Co.Ltd it is 371.24 KRW per share (as of Sep 24, 2026), against a price of 2,615 KRW. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Remed Co.Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 302550 trades above its calculated fair value: price 2,615 KRW, fair value 371.24 KRW, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 302550?
No. The price is what the market pays today (2,615 KRW); the fair value is what the company's own numbers justify (371.24 KRW). For Remed Co.Ltd the two are 2,244 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Remed Co.Ltd worth?
The market values Remed Co.Ltd at about 80.8B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,615 KRW; our models calculate a fair value of 371.24 KRW per share.
What do the bullish and bearish scenarios say about 302550?
Our models span a range for Remed Co.Ltd: cautious scenario 351.08 KRW, base 371.24 KRW, optimistic 448.96 KRW per share (as of Sep 24, 2026, price 2,615 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Remed Co.Ltd (302550)?
Balance-sheet figures for Remed Co.Ltd (as of Sep 24, 2026): return on equity 1.8%, debt of 0.07 per unit of equity. They feed the Quality Score of 49/100, which measures business quality independently of the share price.
How far is 302550 from its 52-week high?
Remed Co.Ltd trades at 2,615 KRW, about 29% below its 52-week high of 3,690 KRW and 5% above the low of 2,485 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 371.24 KRW is for.
Which stocks are comparable to Remed Co.Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Remed Co.Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 2,615 KRW, calculated fair value 371.24 KRW (−86%), Quality Score 49/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 302550 calculated?
We run Remed Co.Ltd through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 371.24 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Remed Co.Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Remed Co.Ltd (302550)?
The closing price on Sep 23, 2026 was 2,615 KRW. Our model-based fair value is 371.24 KRW, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Remed Co.Ltd right now?
The price sits above even our optimistic bull case (448.96 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (49/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Remed Co.Ltd
How large is the market capitalisation of Remed Co.Ltd (302550)?
The market capitalisation of Remed Co.Ltd is 80.8B KRW (≈ $59.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Remed Co.Ltd (302550)?
The price-to-sales ratio of Remed Co.Ltd is 3.21 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Remed Co.Ltd (302550)?
The net margin of Remed Co.Ltd is 2.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Remed Co.Ltd (302550)?
The return on equity (ROE) of Remed Co.Ltd is 1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Remed Co.Ltd (302550)?
On an EBIT basis the return on assets of Remed Co.Ltd is 1.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Remed Co.Ltd (302550)?
The operating margin of Remed Co.Ltd is 9.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Remed Co.Ltd (302550)?
Revenue at Remed Co.Ltd is growing +11.4% versus a year earlier (3y avg +4.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Remed Co.Ltd (302550)?
Earnings per share at Remed Co.Ltd are growing +142% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Remed Co.Ltd (302550) carry?
The net debt of Remed Co.Ltd is 1.8B KRW (fiscal year 2024, ≈ 1.2 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Remed Co.Ltd in the live analysis
One click puts Remed Co.Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
